Sinocare Global
@sinocare.com
Sinocare (Stock Code: 300298) was founded in 2002, dedicated to providing high-quality products and services for patients with chronic diseases such as diabetes, helping them improve their quality of life. The products cover multiple indicators such as blood glucose, blood lipids, and uric acid. They offer a variety of Sinocare blood glucose meters including the Gold AQ Plus series, Safe AQ max Series, and One Sinocare series, as well as UG series, EA-11, UA-I Sinocare medical uric acid meters, and other products like blood pressure monitors and glycated hemoglobin analyzers.
Sinocare Global's Company Logos
Sinocare Global's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#2A8888
Lochinvar
42, 136, 136
180, 53, 35
69, 0, 0, 47
#9EB6DB
Pigeon Post
158, 182, 219
216, 46, 74
28, 17, 0, 14
#000000
Black
0, 0, 0
0, 0, 0
0, 0, 0, 100
About Sinocare Global
Sinocare is a prominent Chinese healthcare company that specializes in research, development, manufacturing, and distribution of medical testing devices for the management of diabetes and other chronic diseases. Founded in 2002, it has established itself as a leading player in the global healthcare market. Headquartered in Changsha, Hunan Province, Sinocare operates a state-of-the-art production facility with advanced technologies and equipment.
The company focuses on producing advanced blood glucose monitoring systems, insulin delivery systems, and other related medical products. Sinocare products are known for their accuracy, ease of use, and affordability, making them accessible to a wide range of patients. In terms of global operations, Sinocare has expanded its footprint to over 130 countries worldwide.
It has established subsidiaries and offices in the United States, Europe, Australia, and Southeast Asia. Additionally, the company has formed strategic partnerships and joint ventures with renowned healthcare companies, positioning it as a key player in the global diabetes management market. Sinocare has achieved significant market success, with a robust sales performance globally.
It has made a notable impact with its products' acceptance amongst healthcare providers, pharmacies, and end-users. The company is highly regarded for its continuous innovation, quality control, and reliable customer service, which has helped it establish a strong competitive position in the market. Noteworthy achievements include the acquisition of Nipro Diagnostics in 2017, a move that significantly expanded Sinocare's market reach and product portfolio.
Additionally, Sinocare has focused on developing strategic partnerships with renowned pharmaceutical companies to enhance its offerings and visibility. As of the latest updates, Sinocare continues to grow and innovate, with an increased focus on expanding its market presence globally. The company remains committed to investing in research and development to introduce new products and technologies into the market.
Sinocare's dedication to improving the lives of patients with chronic diseases has positioned it as a key player in the healthcare industry, with a promising future ahead
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
1001-5000 employees
